AKT1 and cancer: For example, at physiological concentrations, EGCG is an ATP-competitive inhibitor of both PI3K and mammalian target of rapamycin (mTOR); thus, exerting its anti-cancer effect by inhibiting Akt phosphorylation and cell proliferation [45].